Daehan New Pharm Co (XKRX:054670) Debt-to-Equity : 0.30 (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Daehan New Pharm Co Debt-to-Equity?

Daehan New Pharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩35,045 Mil. Daehan New Pharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩312 Mil. Daehan New Pharm Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩117,960 Mil. Daehan New Pharm Co's debt to equity for the quarter that ended in Mar. 2024 was 0.30.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Daehan New Pharm Co's Debt-to-Equity or its related term are showing as below:

XKRX:054670' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29 Med: 0.53 Max: 1.04
Current: 0.3

During the past 13 years, the highest Debt-to-Equity Ratio of Daehan New Pharm Co was 1.04. The lowest was 0.29. And the median was 0.53.

XKRX:054670's Debt-to-Equity is ranked better than
50.12% of 844 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs XKRX:054670: 0.30

Daehan New Pharm Co Debt-to-Equity Historical Data

The historical data trend for Daehan New Pharm Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daehan New Pharm Co Debt-to-Equity Chart

Daehan New Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.61

0.66

0.45

0.36

0.34

Daehan New Pharm Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.29	0.29	0.32	0.34	0.30

Competitive Comparison of Daehan New Pharm Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Daehan New Pharm Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daehan New Pharm Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daehan New Pharm Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Daehan New Pharm Co's Debt-to-Equity falls into.

Daehan New Pharm Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Daehan New Pharm Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(36228.575	+	369.212)	/	109355.896
	=	0.33

Daehan New Pharm Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(35044.979	+	311.681)	/	117959.978
	=	0.30

Daehan New Pharm Co (XKRX:054670) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Daehan New Pharm Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Daehan New Pharm Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Daehan New Pharm Co (XKRX:054670) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daehan New Pharm Co Ltd (XKRX:054670) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

1062-4 Namhyeon-dong, Gwanak-gu, Seoul, KOR, 137-851

Website

http://www.dhnp.co.kr

Daehan New Pharm Co Ltd is a South Korea based company operating in the pharmaceutical sector. It is engaged in producing pharmaceutical products, animal health and nutrition, and bio products. The pharmaceutical products are tertan tab, amloc tab, tarocin SR tab, NP star tab and others. The animal health and nutrition products are starvac, pigcoc for calves, ocean doctor, and others. The bio range of the products by the group are CELRENA serum-free, BMPro serum-free, BMPro-V serum-free, ALyS505NK-EX serum-free and others.

Daehan New Pharm Co (XKRX:054670) Headlines

No Headlines